Anita Davidson, DPT, Founder And CEO and Donald Davidson, PH.D., Founder And CSOLike many great stories, it began with two young dreamers finding their way in the world. In the quiet hallways of a Midwestern high school in the 1970s, two teenagers—Anita, with her sharp wit and boundless empathy, and Don, a restless visionary with a microscope permanently lodged in his imagination—found each other.
They were an unlikely pair: she, the future physical therapist who saw the human body as a symphony of stories; he, the boy who had written a sixth-grade essay vowing to “cure cancer” after watching his grandmother fade away. But love, like science, thrives on unexpected reactions.
For over 40 years, their marriage became a laboratory of shared purpose.
Don pursued biochemistry at Notre Dame before joining Abbott Labs to design cutting-edge cancer therapies. Yet corporate constraints stifled him—a breakthrough drug for brain tumors, dismissed because its mechanism was not fully understood, was shelved indefinitely.
“Science demands answers,” his bosses said. Don seethed. Somewhere, a clock was ticking.
Meanwhile, Anita built her own empire of care. What started in hospitals and chronic pain programs as her growing passion to expand into the ”business of healthcare” to drive more diverse treatments concurrently with a full patient schedule led to finally taking Don’s advice. She started a private practice in the room over the garage—dubbed “Creative Rehab” by their children. Future business ventures were added, but the ghosts of her patients with cancer haunted her: the 16-year-old athlete whose laughter turned to silence after an amputation, the college roommate Carolyn, whose metastatic breast cancer outran every treatment.
Their dinner table became a battleground of frustration. Don scribbled equations on napkins; Anita recounted the labyrinth of insurance bureaucracy and systemic failures.
Whether in cancer, neurodegeneration, or virology, our biologic therapies have the potential to reshape treatment paradigms
Don hesitated—the risk was enormous—but Anita’s conviction was gravitational. The next day, he resigned from AbbVie.
The Birth of Creative BioTherapeutics
Creative BioTherapeutics (CBT) was forged in the friction of their dual genius: Don’s drug-design brilliance and Anita’s relentless empathy and passion for business development. They bootstrapped the venture with profits from her clinics, their kitchen table transforming into a war room.
Don revisited his abandoned drug and saw what had been overlooked—it didn’t directly attack tumors but instead awakened the immune system, a revelation years ahead of its time.
Anita, ever the pragmatist, navigated the drug development timelines, engaging research support and fund raising to drive CBT through the regulatory mazes and funding droughts. Her mantra: Patients can’t wait for perfect.
Their breakthroughs were hard-won. Don engineered therapies to dismantle cancer’s “invisibility cloak,” a cellsurface mechanism he had identified decades earlier. Anita championed non-toxic, affordable treatments, her frustration with six-figure treatment and toxic chemotherapy costs fueling her negotiations. When the National Science Foundation finally backed their vision, it wasn’t just a validation of science—it was a triumph of stubborn hope.
A Revolution in Cancer Treatment
Today, CBT stands on the precipice of revolution. A private equity firm whispers promises of funding to bring a novel market disruptive cure to patients. Don’s newly designed drug, refined and fully understood, has the potential to rewrite oncology. Anita’s wall of patients photos—those luminous, lost faces—gazes down as they work, a silent chorus urging them onward.
-
We are working to change that narrative by developing biologic therapies that directly address drug resistance—one of the fundamental reasons why so many treatments fail
At the heart of CBT’s mission is CBT 300, a first-inclass therapy designed to overcome drug resistance in late-stage cancer and other diseases where resistance mechanisms hinder effective treatment. CBT prioritizes safe, effective, and non-toxic solutions for some of the world’s most challenging diseases.
The Persistent Challenge of Drug Resistance
Cancer treatments often lose effectiveness as tumorsdevelop resistance, leading to recurrence, metastasis, and treatment failure. A key culprit is a stress protein activated by traditional therapies, which helps cancer cells expel drugs, evade immune attacks, and spread aggressively. This resistance makes late-stage cancers incredibly difficult to treat, with standard therapies offering only limited life extension.
CBT aims to break this cycle by targeting resistance mechanisms, giving patients not just prolonged survival but the potential for long-term remission. By disrupting cancer’s adaptability, CBT seeks to transform oncology outcomes and offer hope for a durable response to treatment.
“Cancer remains one of the biggest medical challenges, impacting millions. Despite advances in targeted therapies and immunotherapy, drug resistance remains a major barrier to long-term survival,” says Donald Davidson, Ph.D., CSO and founder of Creative BioTherapeutics. “We are working to change that narrative by developing biologic therapies that directly address drug resistance—one of the fundamental reasons why so many treatments fail.”
A Game-Changer in Cancer Therapy
CBT 300 is designed to neutralize the stress protein that drives drug resistance. By removing this protein, CBT 300 accomplishes three critical objectives:
1. Restores Chemotherapy Sensitivity
By disabling drug-efflux pumps, CBT 300 allows chemotherapy to remain inside cancer cells, making treatment significantly more effective. Lower chemotherapy doses can be used while maintaining or improving outcomes, reducing toxic side effects.
2. Enhances Immunotherapy Efficacy
Removing cancer’s protective shield enables the immune system to recognize and attack tumors more effectively, making CBT 300 a powerful combination therapy with existing immunotherapies.
3. Prevents Metastasis and Cancer Stem Cell Formation
By blocking the mechanisms that allow cancer to spread and regenerate, CBT 300 significantly reduces the risk of recurrence, a key factor in improving long-term survival.
Preclinical studies have shown exceptional promise. In models of triple-negative breast cancer—a highly aggressive and drug-resistant form of the disease—CBT 300 achieved an 88% survival rate. Drug-resistant renal, lung and melanoma cancer models also demonstrated substantial improvement, suggesting broad applicability across multiple solid tumor types.
Expanding Beyond Cancer
While CBT 300’s primary focus is oncology, its potential applications extend beyond cancer. The same stress protein that fuels drug resistance in tumors also plays a role in neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as persistent viral infections. CBT is exploring how its technology could be adapted to treat these conditions, opening the door to new therapeutic possibilities.
“Whether in cancer, neurodegeneration, or virology, our biologic therapies have the potential to reshape treatment paradigms,” says Anita Davidson, DPT, founder and CEO of Creative BioTherapeutics.
Rethinking Success in Cancer Treatment
Most cancer drugs today are evaluated based on progression-free survival—the amount of time before the disease worsens. While this metric is important, it often does not translate to actual long-term survival. Many treatments extend progression-free survival by only a few months without preventing recurrence.
CBT is aiming higher.
Its goal is not just to delay progression but to achieve complete tumor eradication ensuring overall survival. If successful, CBT 300 could mark a fundamental shift in how we approach cancer treatment—moving from managing the disease to curing it.
The company is moving swiftly to bring CBT 300 into clinical trials, driven by a deep sense of urgency for patients with few options. CBT is also actively exploring strategic partnerships with pharmaceutical firms to accelerate development and expand access to its therapies.
While challenges remain, CBT’s approach is grounded in rigorous science and a deep understanding of cancer’s resistance mechanisms. If successful, its work could redefine how we treat cancer and provide hope to millions.
More Than Just a Company—A Legacy
CBT is not just another biotech company—it is a missiondriven force seeking to transform the way we treat some of the world’s deadliest diseases. By tackling drug resistance head-on, it is pioneering a new era of cancer treatment that prioritizes effectiveness, safety, and long-term survival.
CBT’s story isn’t just about cancer.
It’s about a boy who never outgrew his sixth-grade dream, a healer who refused to accept limits, and the alchemy of two lifetimes fused into a single, unyielding light.
And somewhere, a 16-year-old girl is still running, her legs unbroken, her breath eternal, watching as Anita and Don turn four decades of grit into a legacy—where love and science defy the impossible, one cure at a time.
Breaking the Cancer Drug Resistance Barrier
One of the biggest frustrations in oncology today is that many cancer therapies initially work as intended, only for the disease to adapt over time. Tumors evolve, immune responses weaken and recurrence becomes increasingly difficult to control with each additional line of treatment. For biotech executives evaluating acquisition targets or partnership opportunities, that reality has changed how oncology assets are assessed. Producing an early response is no longer enough. Buyers increasingly want programs that address the underlying mechanisms behind resistance and recurrence, particularly in aggressive or recurrent solid tumors where long-term outcomes remain limited.
That shift has also changed what makes an oncology platform commercially attractive. A therapy designed to target drug resistance can create value beyond a single indication if the biology behind the approach applies across multiple tumor settings. Companies that can restore sensitivity to existing therapies or improve immune recognition may fit more naturally into current standards of care than programs attempting to replace them entirely. From a development standpoint, that flexibility matters because it creates more room for combination studies, strategic partnerships and broader clinical expansion without forcing healthcare systems to adopt completely new treatment models.
At the same time, buyers have become more cautious about programs that sound promising at the mechanism level but lack convincing translational evidence. Drug-resistance research is full of concepts that generate strong laboratory data yet struggle once they move into clinically relevant settings. As a result, executives tend to focus closely on whether a company can show meaningful evidence tied to real therapeutic challenges, including recurrence control, immune activity, tolerability and durability of response. Breadth across cancer types can be valuable, but only when there is a clear biological explanation for why the mechanism should work consistently across those diseases.
The economics of oncology treatment are also influencing how these platforms are viewed. Late-stage cancer care is increasingly expensive and physically demanding for patients, particularly when multiple therapies are layered together with limited added benefit. That has created more interest in approaches that may improve the effectiveness of existing regimens without significantly increasing toxicity or treatment burden. Programs that can work alongside chemotherapy or immunotherapy, particularly at lower exposure levels, may ultimately fit more realistically into payer expectations and clinical practice.
In this environment, the strongest oncology companies are often the ones that stay tightly focused on a clearly defined therapeutic problem rather than positioning themselves as broadly disruptive across every area of cancer care. Investors and acquirers want to see a direct connection between the biology, the development strategy and the intended clinical use. Scientific ambition still matters, but it has to be matched by a realistic path toward adoption and clinical relevance.
Creative BioTherapeutics has centered its development strategy on the challenge of cancer drug resistance and immune evasion. Its lead program, CBT300, is being developed as a biologic for recurrent cancers, with the goal of restoring chemotherapy sensitivity while also supporting immune activation. Early preclinical work has explored the approach across breast, brain, lung, colon, melanoma, ovarian and renal cancer models. What makes the platform notable is the way it brings together resistance reversal, immune engagement and recurrence control within a single therapeutic framework. For executives evaluating oncology companies with partnership or licensing potential, Creative BioTherapeutics offers a focused and commercially relevant approach to one of the most persistent problems in cancer treatment.
...Read more
Cancer Drug Resistance Info
Q1
Why is Creative Biotherapeutics recognized among Top Cancer Drug Resistance Companies?
Creative Biotherapeutics is recognized in the Cancer Drug Resistance Company space because it directly targets one of the biggest barriers in oncology: therapy resistance. Its lead biologic CBT300 is designed to neutralize cellular survival mechanisms that allow tumors to evade chemotherapy and immunotherapy. This focus on reversing resistance rather than only slowing tumor growth positions it among specialized innovators in Cancer Drug Resistance Company research.
Q2
What makes CBT LLC’s approach different from traditional oncology companies?
Unlike conventional oncology approaches that focus primarily on cytotoxic killing or immune activation, CBT LLC’s Cancer Drug Resistance Company strategy targets the biological pathways that enable cancer cells to survive treatment. The platform is built around disrupting stress-response proteins linked to drug efflux and immune evasion, allowing existing therapies to become more effective when used in combination with CBT300.
Q3
How does CBT300 work within its Cancer Drug Resistance Company pipeline?
CBT300 is a biologic therapy designed to block a key survival protein that cancer cells use under treatment stress. By inhibiting this pathway, the Cancer Drug Resistance Company approach restores chemotherapy sensitivity, enhances immune system recognition of tumors and reduces metastatic potential. Preclinical studies have shown tumor regression and improved survival outcomes in multiple resistant cancer models, including breast and lung cancers.
Q4
What role does drug resistance biology play in CBT LLC’s research model?
Drug resistance biology is the central focus of the Cancer Drug Resistance Company framework at CBT LLC. Instead of treating cancer as a single disease, it studies how tumors adapt under therapeutic pressure. This includes stress protein activation, immune evasion and cancer stem cell survival. By targeting these mechanisms, CBT aims to extend treatment durability and improve long-term response rates across solid tumors.
Q5
What role does drug resistance biology play in CBT LLC’s research model?
Drug resistance biology is the central focus of the Cancer Drug Resistance Company framework at CBT LLC. Instead of treating cancer as a single disease, it studies how tumors adapt under therapeutic pressure. This includes stress protein activation, immune evasion and cancer stem cell survival. By targeting these mechanisms, CBT aims to extend treatment durability and improve long-term response rates across solid tumors.
Q6
How does CBT LLC aim to improve outcomes in late-stage cancers?
The Cancer Drug Resistance Company model at CBT LLC focuses on late-stage and recurrent cancers where standard therapies often fail. By combining CBT300 with existing chemotherapy or immunotherapy, the company aims to restore treatment effectiveness and reduce relapse rates. Preclinical data indicate improved survival outcomes in aggressive tumor models, supporting its potential role in advanced oncology care strategies.
Q7
Why is Creative Biotherapeutics important for the future of oncology?
Creative Biotherapeutics is important because it shifts the focus of cancer research toward resistance reversal rather than incremental treatment improvement. As a Cancer Drug Resistance Company, it addresses one of the most persistent challenges in oncology—why tumors stop responding to therapy. This approach could support more durable responses and expand treatment possibilities for patients with limited options in late-stage disease settings.
Q8
Why is Creative Biotherapeutics important for the future of oncology?
Creative Biotherapeutics is important because it shifts the focus of cancer research toward resistance reversal rather than incremental treatment improvement. As a Cancer Drug Resistance Company, it addresses one of the most persistent challenges in oncology—why tumors stop responding to therapy. This approach could support more durable responses and expand treatment possibilities for patients with limited options in late-stage disease settings.
